Loading..

Immatics N.V. (IMTX) Report Analysis

Corporate Events

Neutral

Immatics N.V. has filed a Shelf Registration in...

2022-06-24 00:00:00

Immatics N.V. has filed a Shelf Registration in the amount of $39.490108 million. Security Name: Ordinary Shares Securities Offered: 4,845...

Neutral

Eberhard Karls Universität Tübingen, Tübinger S...

2022-06-23 14:42:00

Eberhard Karls Universität Tübingen, Tübinger Science & Innovation Days 2022, Jun 29, 2022 through Jul 02, 2022. Venue: Tubingen, Germany.

Neutral

Immatics N.V. Presents at Tübinger Science & In...

2022-06-23 14:42:00

Immatics N.V. Presents at Tübinger Science & Innovation Days 2022, Jun-29-2022 through Jul-02-2022. Venue: Tubingen, Germany. Presentation Dat...

Neutral

Immatics US, Inc., Entered into A Collaboration...

2022-06-13 12:26:00

On June 1, 2022, a subsidiary of Immatics N.V., Immatics US Inc., entered into a Collaboration Agreement with a subsidiary of Bristol-Myers Sq...

Neutral

Immatics N.V. and Editas Medicine, Inc. Enter S...

2022-06-07 11:00:00

Immatics N.V. and Editas Medicine, Inc. announced that the two companies have entered into a strategic research collaboration and licensing ag...

Positive

Immatics N.V. and Bristol Myers Squibb Expand S...

2022-06-02 11:02:00

Immatics N.V. and Bristol Myers Squibb announced that they have expanded their strategic alliance to pursue the development of multiple alloge...

Neutral

Immatics N.V., Annual General Meeting, Jun 13, 2022

2022-05-27 06:12:00

Immatics N.V., Annual General Meeting, Jun 13, 2022, at 14:00 Central European Standard Time. Location: the offices of NautaDutilh N.V., Beeth...

Positive

Immatics N.V. Announces First Patient Treated w...

2022-05-18 11:00:00

Immatics N.V. announced that the first patient has been dosed in the IMA203 and nivolumab combination Phase 1b dose expansion cohort. This coh...

Positive

Immatics Initiates Phase 1 Clinical Trial to Ev...

2022-05-10 11:00:00

Immatics N.V. announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER®) IMA401 for patients with recurren...

Neutral

Immatics N.V. Presents at 14th Kempen Life Scie...

2022-03-29 06:52:00

Immatics N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022 . Venue: Amsterdam, Netherlands.

Neutral

Immatics N.V. Presents at Bank of America 2022 ...

2022-03-22 05:03:00

Immatics N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 . Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Ne...

Neutral

Immatics N.V. Presents at Goldman Sachs 43rd An...

2022-03-21 20:41:00

Immatics N.V. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 . Venue: Terranea Resort, Rancho Palos Verdes, C...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Neutral

American Association For Cancer Research, AACR ...

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Cent...

Neutral

Hanson Wade Limited, Supply Chain & Logistics f...

2022-01-13 18:45:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Apr 25, 2022 through Apr 27, 2022. Venue: Boston, United States.

Neutral

Immatics N.V. Presents at Supply Chain & Logist...

2022-01-13 18:45:00

Immatics N.V. Presents at Supply Chain & Logistics for Cell Therapies Summit, Apr-25-2022 . Venue: Boston, United States.

Neutral

Immatics N.V. Presents at AACR Annual Meeting 2...

2022-01-13 18:45:00

Immatics N.V. Presents at AACR Annual Meeting 2022, Apr-08-2022 . Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Cancer Immunotherapy and Immunomonitoring, CIT...

2022-01-13 18:45:00

Cancer Immunotherapy and Immunomonitoring, CITIM Meeting 2022, Apr 25, 2022 through Apr 28, 2022. Venue: Vilnius, Lithuania.

Neutral

Cambridge Innovation Institute, LLC, PEGS Bosto...

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Immatics N.V. Presents at CITIM Meeting 2022, A...

2022-01-13 18:45:00

Immatics N.V. Presents at CITIM Meeting 2022, Apr-25-2022 . Venue: Vilnius, Lithuania.

Neutral

Immatics N.V. Presents at Annual Onco Cell Ther...

2022-01-13 18:45:00

Immatics N.V. Presents at Annual Onco Cell Therapy Summit, Jun-29-2022 . Venue: Boston, United States.

Neutral

Immatics N.V. Presents at PEGS Boston Conferenc...

2022-01-13 18:45:00

Immatics N.V. Presents at PEGS Boston Conference 2022, May-02-2022 . Venue: Boston, Massachusetts, United States.

Neutral

Immatics N.V. Presents at The 2022 ASCO Annual ...

2022-01-13 18:45:00

Immatics N.V. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Association for Cancer Immunotherapy, CIMT Ann...

2022-01-13 18:45:00

Association for Cancer Immunotherapy, CIMT Annual Meeting 2022, May 10, 2022 through May 12, 2022. Venue: Mainz, Germany.

Neutral

Immatics N.V. Presents at CIMT Annual Meeting 2...

2022-01-13 18:45:00

Immatics N.V. Presents at CIMT Annual Meeting 2022, May-10-2022 . Venue: Mainz, Germany.

Neutral

Enterprise Europe Network, Open Innovation Kong...

2022-01-13 08:51:00

Enterprise Europe Network, Open Innovation Kongress Baden-Württemberg 2022, Apr 11, 2022. Venue: Stuttgart, Germany.

Neutral

Immatics N.V. Presents at Open Innovation Kongr...

2022-01-13 08:51:00

Immatics N.V. Presents at Open Innovation Kongress Baden-Württemberg 2022, Apr-11-2022 . Venue: Stuttgart, Germany.

Neutral

Kisaco Research, Annual Onco Cell Therapy Summi...

2021-12-26 17:53:00

Kisaco Research, Annual Onco Cell Therapy Summit, Jun 29, 2022 through Jun 30, 2022. Venue: Boston, United States.

Neutral

Immatics N.V. Presents at LifeSci Partners 11th...

2021-12-16 17:17:00

Immatics N.V. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022 .

Neutral

Immatics and Bristol Myers Squibb Enter into Gl...

2021-12-14 12:22:00

Immatics N.V. and Bristol Myers Squibb announced that they have entered into a license, development and commercialization agreement (the “agre...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

Immatics N.V. Presents at Piper Sandler 33rd An...

2021-11-22 15:06:00

Immatics N.V. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

LifeSci Partners, LifeSci Partners 11th Annual ...

2021-11-20 00:00:00

LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022.

Neutral

Kempen & Co, 14th Kempen Life Sciences Conferen...

2021-11-13 00:00:00

Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022. Venue: Amsterdam, Netherlands.

Neutral

Immatics N.V. - Special Call

2021-11-09 13:08:00

To discuss these clinical data and the company’s comprehensive strategy to target PRAME via different programs

Positive

Immatics Reports Clinical Responses across Mult...

2021-11-09 13:00:00

Immatics N.V. announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine® IMA203 targeting PRAM...

Neutral

Immatics N.V. Presents at 12th Annual Jefferies...

2021-11-02 14:13:00

Immatics N.V. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 . Venue: London, United Kingdom.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Immatics N.V. Presents at Festival of Biologics...

2021-10-11 18:52:00

Immatics N.V. Presents at Festival of Biologics Basel 2021, Nov-09-2021 through Nov-11-2021. Venue: Congress Centre, Basel, Switzerland. Prese...

Neutral

Immatics N.V. Presents at Antibody Engineering ...

2021-10-06 12:38:00

Immatics N.V. Presents at Antibody Engineering & Therapeutics US, Dec-15-2021 03:15 PM. Venue: Marriott Marquis San Diego, San Diego, Californ...

Neutral

Immatics N.V. Presents at Cell & Gene Therapy B...

2021-09-16 14:42:00

Immatics N.V. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021 . Speakers: Ali Mohamed, Ali Mohamed.

Neutral

Immatics N.V. Presents at Advanced Therapies Co...

2021-09-09 09:19:00

Immatics N.V. Presents at Advanced Therapies Connect, Sep-28-2021 01:30 PM. Speakers: Delfi Krishna, Head of Strategic Operations, Cell & Gene...

Neutral

Clarion Events Limited, Advanced Therapies Conn...

2021-09-09 04:36:00

Clarion Events Limited, Advanced Therapies Connect, Sep 28, 2021 through Sep 29, 2021.

Neutral

Informa plc, Cell & Gene Therapy Bioprocessing ...

2021-09-08 23:01:00

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021.

Neutral

Immatics N.V. Presents at 6th Annual CAR-TCR Su...

2021-08-24 14:32:00

Immatics N.V. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 through Sep-03-2021. Venue: Hynes Convention Center, Boston, Massachusetts, U...

Neutral

Immatics N.V. Presents at Supply Chain & Logist...

2021-08-14 17:42:00

Immatics N.V. Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-27-2021 04:30 PM. Speakers: Delfi Krishna, Head of Strategic...

Neutral

Hanson Wade Limited, Supply Chain & Logistics f...

2021-08-14 15:18:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021.

Neutral

Immatics N.V. Presents at BTIG Virtual Biotechn...

2021-08-04 12:33:00

Immatics N.V. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 11:00 AM. Speakers: Arnd Christ, Chief Financial Officer, Harpree...

Neutral

Immatics N.V. has filed a Shelf Registration in...

2021-08-02 00:00:00

Immatics N.V. has filed a Shelf Registration in the amount of $500 million. Security Name: Ordinary shares Security Name: Debt securitie...

Negative

Immatics N.V. has filed a Follow-on Equity Offe...

2021-08-02 00:00:00

Immatics N.V. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common St...

Positive

Biocopy AG and Immatics Enter into a Collaborat...

2021-07-07 07:00:00

BioCopy AG announced a collaboration with Immatics N.V. Immatics in the field of characterization of T cell receptors (TCRs). T cell receptors...

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conferenc...

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Neutral

Immatics N.V. has filed a Shelf Registration in the amount of $39.490108 million.

2022-06-24 00:00:00

Immatics N.V. has filed a Shelf Registration in the amount of $39.490108 million. Security Name: Ordinary Shares Securities Offered: 4,845,412 Transaction Features: ESOP Related Offering

Neutral

Eberhard Karls Universität Tübingen, Tübinger Science & Innovation Days 2022, Jun 29, 2022 through Jul 02, 2022

2022-06-23 14:42:00

Eberhard Karls Universität Tübingen, Tübinger Science & Innovation Days 2022, Jun 29, 2022 through Jul 02, 2022. Venue: Tubingen, Germany.

Neutral

Immatics N.V. Presents at Tübinger Science & Innovation Days 2022, Jun-29-2022 through Jul-02-2022

2022-06-23 14:42:00

Immatics N.V. Presents at Tübinger Science & Innovation Days 2022, Jun-29-2022 through Jul-02-2022. Venue: Tubingen, Germany. Presentation Date & Speakers: Jun-29-2022, Oliver Schoor, Vice President Target Research. Jun-30-2022, Oliver Schoor, Vice President Target Research.

Neutral

Immatics US, Inc., Entered into A Collaboration Agreement with Celgene Switzerland LLC

2022-06-13 12:26:00

On June 1, 2022, a subsidiary of Immatics N.V., Immatics US Inc., entered into a Collaboration Agreement with a subsidiary of Bristol-Myers Squibb Company Celgene Switzerland LLC, relating to the development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs. Pursuant to the Agreement, Bristol-Myers Squibb has the initial right, but not the obligation, to designate up to two receptors and associated targets selected from (i) T-cell receptors and associated TCR targets that are the subject of the Company’s 2019 strategic collaboration and license agreement with Bristol-Myers Squibb and (ii) chimeric antigen receptors and associated CAR targets provided by BMS for development as allogeneic cell therapy products as set forth in a mutually agreed research plan. Up to the ten year anniversary of the Agreement, Bristol-Myers Squibb may additionally designate up to four additional such TCRs and associated TCR targets and/or CARs and associated CAR targets for development solely by Bristol-Myers Squibb as allogeneic cell therapy products After preclinical development of the Initial BMS Products, for which Immatics will be responsible, Bristol-Myers Squibb will be responsible for, and bear the cost of, the remaining development and commercialization. Bristol-Myers Squibb also will be responsible for, and bear the cost of, the development and commercialization of any Additional BMS Products. Further, pursuant to the Agreement, prior to the ten year anniversary of the Agreement, Immatics has the right, but not the obligation, to designate up to four TCRs that are not subject to the Agreement or the Company’s 2019 strategic collaboration and license agreement with Bristol-Myers Squibb for collaboration with Bristol-Myers Squibb on their development as allogeneic cell therapy products Immatics will be responsible for, and bear the cost of, the development and commercialization of any Immatics Products; provided that Bristol-Myers Squibb has a right to opt-in to co-develop and co-commercialize one of the first two such Immatics Products. Bristol-Myers Squibb will pay to Immatics a $60 million upfront payment. Immatics is also eligible to receive additional payments for certain activities that Immatics could perform at Bristol-Myers Squibb’s request and for Bristol-Myers Squibb’s designation of additional CARs and/or TCRs for development, as described above. Further, Immatics is also eligible to receive milestone payments of up to $700 million depending on product characteristics and the achievement of certain regulatory and commercial milestones. In addition, during the royalty term (as described below) and depending on certain product characteristics, (i) Immatics will be eligible to receive tiered, mid-single-digit up to low double-digit percentage royalties on worldwide net sales of BMS Products, and (ii) Bristol-Myers Squibb will be eligible to receive tiered, low- to mid-single-digit percentage royalties on worldwide net sales of Immatics Products except in the case of an Immatics Product for which Bristol-Myers Squibb is co-developing and co-commercializing. The royalty percentages described above are subject to reduction in a given country under certain circumstances, including, but not limited to, the introduction of biosimilar products and third party license costs.

Neutral

Immatics N.V. and Editas Medicine, Inc. Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

2022-06-07 11:00:00

Immatics N.V. and Editas Medicine, Inc. announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine’s CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institute’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. By combining Editas Medicine’s gene editing technology with Immatics’ ACTallo® allogeneic, off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, gamma-delta T cells can be redirected to cancer cell targets with the goal of creating cells with enhanced tumor recognition and destruction. Under the terms of the agreement, Editas Medicine will be eligible to receive an undisclosed upfront cash payment as well as additional milestone payments based on development, regulatory, and commercial milestones. In addition, Immatics will pay royalties on future net sales on any products that may result from this collaboration.

Positive

Immatics N.V. and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

2022-06-02 11:02:00

Immatics N.V. and Bristol Myers Squibb announced that they have expanded their strategic alliance to pursue the development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs. Under this collaboration, Bristol Myers Squibb and Immatics will develop two programs owned by Bristol Myers Squibb and both companies have an option to develop up to four additional programs each. The programs will utilize Immatics’ proprietary gamma delta T cell-derived, allogeneic Adoptive Cell Therapy (ACT) platform, called ACTallo, and a suite of next-generation technologies developed by Bristol Myers Squibb. Under the terms of this agreement, Immatics will receive an upfront payment of $60 million as well as up to $700 million per Bristol Myers Squibb program through development, regulatory and commercial milestone payments and tiered royalty payments of up to low double-digit percentages on net product sales. Immatics will be responsible for preclinical development of the initial two Bristol Myers Squibb-owned programs and will receive additional payment for certain activities that Immatics could perform at Bristol Myers Squibb’s request. Bristol Myers Squibb will assume responsibility for clinical development and commercialization activities of all Bristol Myers Squibb-owned programs thereafter. In addition, Bristol Myers Squibb and Immatics will expand their 2019 collaboration agreement focused on autologous T cell receptor-based therapy (TCR-T), with the inclusion of one additional TCR target discovered by Immatics. As part of this expansion, Immatics will receive an upfront payment of $20 million and be eligible for milestone payments and royalties. About ACTallo: ACTallo is Immatics’ proprietary allogeneic, off-the-shelf adoptive cell therapy platform based on gamma delta T cells sourced from healthy donors. Manufacturing process is designed to create hundreds of doses from one single donor leukapheresis. Gamma delta T cells are abundant in the peripheral blood, show intrinsic anti-tumor activity, naturally infiltrate solid tumors and do not cause graft-vs-host disease – characteristics that make this cell type well suited for an allogeneic approach. The ACTallo® process engineers gamma delta T cells with chimeric antigen receptors (CARs) or T cell receptors (TCRs), thus accessing cancer cell surface targets as well as intracellular proteins that are presented as peptides on the surface of the cancer cell. This enables the redirection of gamma delta T cells to cancer cell targets. ACTallo® products will be available for patient treatment without the requirement for personalized manufacturing. Since these T cells originate from healthy individuals, they are not reliant on the potentially encumbered immune system of the cancer patient.

Neutral

Immatics N.V., Annual General Meeting, Jun 13, 2022

2022-05-27 06:12:00

Immatics N.V., Annual General Meeting, Jun 13, 2022, at 14:00 Central European Standard Time. Location: the offices of NautaDutilh N.V., Beethovenstraat 400 Amsterdam Netherlands Agenda: To consider Discussion of the statutory board report regarding the financial year ended 31 December 2021; to consider Discussion of the Company's dividend and reservation policy; to consider Adoption of the statutory annual accounts for the financial year ended 31 December 2021; to consider appointment and Reappointment of Mr. P.A. Chambré as non-executive director class II; to consider Approval of the Company's 2022 stock option and incentive plan; to consider Extension of the authorisation of the Board to acquire ordinary shares or depositary receipts thereof; to consider Instruction to PricewaterhouseCoopers Accountants N.V. as auditor for the financial year ending 31 December 2022; and to consider other related matters.

Positive

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

2022-05-18 11:00:00

Immatics N.V. announced that the first patient has been dosed in the IMA203 and nivolumab combination Phase 1b dose expansion cohort. This cohort will evaluate Immatics’ TCR-engineered cell therapy (TCR-T) approach ACTengine® IMA203 targeting an HLA-A*02-presented peptide derived from PRAME, in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor nivolumab, in patients with advanced solid tumors. The objectives of the study will be to evaluate the safety, biological activity, and initial anti-tumor activity of the IMA203 and nivolumab combination. The IMA203 and nivolumab combination Phase 1b dose expansion cohort is expected to enroll up to 18 patients with different types of solid tumors across 10 clinical trial sites in Germany and the U.S. Bristol Myers Squibb will provide Immatics, the study sponsor of the combination trial, with nivolumab as part of a clinical supply agreement. Nivolumab has become the standard of care treatment for many solid cancer indications and believe it fits well into the IMA203 treatment and observation schedule. According to the clinical trial protocol for ACTengine® IMA203, nivolumab will be administered at regular intervals following IMA203 treatment. The primary endpoint of this cohort is to assess the safety of the combination. Anti-tumor activity resulting from the drug combination is a secondary endpoint, which will be assessed through imaging and measured according to the standard Response Evaluation Criteria In Solid Tumors (RECIST). The combination treatment of IMA203 and nivolumab is part of Immatics' strategy to realize the full clinical potential of IMA203 TCR-T targeting PRAME. Based on this strategy, the company has expanded the IMA203 trial to a total of three Phase 1b dose expansion cohorts – each designed to assess observed objective response rates, demonstrate durability of response, and form the basis for enrollment in pivotal studies. In addition to the IMA203 and nivolumab combination (first patient treated, initial data read-out planned for YE 2022), Immatics will also investigate IMA203 as monotherapy (patient enrollment ongoing, next data read-out planned in 2H 2022) and IMA203CD8, a next-generation cell therapy where IMA203-engineered T cells are co-transduced with a CD8aß co-receptor (initiation planned for Second Quarter 2022, initial data read-out planned for YE 2022). ACTengine® IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME), a protein frequently expressed in a large variety of solid cancers thereby supporting the programs’ potential to address a broad cancer patient population. Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogenously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT®. Through its proprietary TCR discovery and engineering platform XCEPTOR®, Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine® IMA203.

Positive

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

2022-05-10 11:00:00

Immatics N.V. announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER®) IMA401 for patients with recurrent and/or refractory solid tumors. IMA401 is the most advanced product candidate from Immatics’ TCR Bispecific pipeline targeting an HLA-A*02-presented peptide derived from both MAGEA4 and MAGEA8. TCER® IMA401 will be developed in collaboration with Bristol Myers Squibb. Immatics is responsible for conducting the Phase 1 clinical trial. The primary objectives of the clinical trial (NCT#05359445) are to determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) for IMA401 in biomarker-positive (HLA-A*02:01 and MAGEA4/8) patients with recurrent and/or refractory solid tumors. Secondary objectives are to characterize safety and tolerability, evaluate initial anti-tumor activity and assess pharmacokinetics of IMA401. The Phase 1 trial consists of a dose-escalation (Phase 1a) portion that will be followed by a dose-expansion (Phase 1b) portion to treat patients at the recommended dose level. The trial is planned to be conducted at up to 15 centers in Germany, with the first site already being initiated. The Phase 1 trial is designed to enroll approximately 50 patients. Immatics’ TCR Bispecific pipeline includes a second TCER® product candidate, IMA402, which targets PRAME. Manufacturing of the clinical IMA402 batch is planned for the second half of 2022 and initiation of the Phase 1 trial is planned in 2023. Immatics’ TCER® pipeline is further strengthened by additional innovative TCER® program(s), IMA40X, in preclinical development. IMA401 is Immatics’ most advanced TCER® molecule that targets an HLA-A*02-presented (human leukocyte antigen) peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT® and is presented at a 5-fold higher copy number per tumor cell than a MAGEA4 peptide targeted in other clinical trials. Following preclinical proof-of-concept data, including complete remissions of transplanted human-derived tumors in xenograft mouse models, the Phase 1 trial investigates IMA401 in patients with tumors of high MAGEA4/8 prevalence, such as squamous non-small cell lung carcinoma (sqNSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian carcinomas, as well as melanoma, sarcoma subtypes and other solid cancer types.

Neutral

Immatics N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022

2022-03-29 06:52:00

Immatics N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022 . Venue: Amsterdam, Netherlands.

Neutral

Immatics N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2022

2022-03-22 05:03:00

Immatics N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 . Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Arnd Christ, Chief Financial Officer, Harpreet Singh, CEO, MD, Member of Management Board & Supervisory Director, Jordan Silverstein, Head of Strategy.

Neutral

Immatics N.V. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022

2022-03-21 20:41:00

Immatics N.V. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 . Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Apr 25, 2022 through Apr 27, 2022

2022-01-13 18:45:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Apr 25, 2022 through Apr 27, 2022. Venue: Boston, United States.

Neutral

Immatics N.V. Presents at Supply Chain & Logistics for Cell Therapies Summit, Apr-25-2022

2022-01-13 18:45:00

Immatics N.V. Presents at Supply Chain & Logistics for Cell Therapies Summit, Apr-25-2022 . Venue: Boston, United States.

Neutral

Immatics N.V. Presents at AACR Annual Meeting 2022, Apr-08-2022

2022-01-13 18:45:00

Immatics N.V. Presents at AACR Annual Meeting 2022, Apr-08-2022 . Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Cancer Immunotherapy and Immunomonitoring, CITIM Meeting 2022, Apr 25, 2022 through Apr 28, 2022

2022-01-13 18:45:00

Cancer Immunotherapy and Immunomonitoring, CITIM Meeting 2022, Apr 25, 2022 through Apr 28, 2022. Venue: Vilnius, Lithuania.

Neutral

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Neutral

Immatics N.V. Presents at CITIM Meeting 2022, Apr-25-2022

2022-01-13 18:45:00

Immatics N.V. Presents at CITIM Meeting 2022, Apr-25-2022 . Venue: Vilnius, Lithuania.

Neutral

Immatics N.V. Presents at Annual Onco Cell Therapy Summit, Jun-29-2022

2022-01-13 18:45:00

Immatics N.V. Presents at Annual Onco Cell Therapy Summit, Jun-29-2022 . Venue: Boston, United States.

Neutral

Immatics N.V. Presents at PEGS Boston Conference 2022, May-02-2022

2022-01-13 18:45:00

Immatics N.V. Presents at PEGS Boston Conference 2022, May-02-2022 . Venue: Boston, Massachusetts, United States.

Neutral

Immatics N.V. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022

2022-01-13 18:45:00

Immatics N.V. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 . Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Association for Cancer Immunotherapy, CIMT Annual Meeting 2022, May 10, 2022 through May 12, 2022

2022-01-13 18:45:00

Association for Cancer Immunotherapy, CIMT Annual Meeting 2022, May 10, 2022 through May 12, 2022. Venue: Mainz, Germany.

Neutral

Immatics N.V. Presents at CIMT Annual Meeting 2022, May-10-2022

2022-01-13 18:45:00

Immatics N.V. Presents at CIMT Annual Meeting 2022, May-10-2022 . Venue: Mainz, Germany.

Neutral

Enterprise Europe Network, Open Innovation Kongress Baden-Württemberg 2022, Apr 11, 2022

2022-01-13 08:51:00

Enterprise Europe Network, Open Innovation Kongress Baden-Württemberg 2022, Apr 11, 2022. Venue: Stuttgart, Germany.

Neutral

Immatics N.V. Presents at Open Innovation Kongress Baden-Württemberg 2022, Apr-11-2022

2022-01-13 08:51:00

Immatics N.V. Presents at Open Innovation Kongress Baden-Württemberg 2022, Apr-11-2022 . Venue: Stuttgart, Germany.

Neutral

Kisaco Research, Annual Onco Cell Therapy Summit, Jun 29, 2022 through Jun 30, 2022

2021-12-26 17:53:00

Kisaco Research, Annual Onco Cell Therapy Summit, Jun 29, 2022 through Jun 30, 2022. Venue: Boston, United States.

Neutral

Immatics N.V. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022

2021-12-16 17:17:00

Immatics N.V. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022 .

Neutral

Immatics and Bristol Myers Squibb Enter into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

2021-12-14 12:22:00

Immatics N.V. and Bristol Myers Squibb announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, IMA401. Under the terms of the agreement, Immatics will receive an upfront payment of $150 million as well as up to $770 million in development, regulatory and commercial milestone payments, in addition to tiered double-digit royalty payments on net sales of IMA401. Immatics retains the options to co-fund U.S. development in exchange for enhanced U.S. royalty payments and/or to co-promote IMA401 in the US. IMA401 is the most advanced product candidate in Immatics’ TCR Bispecifics pipeline, called TCER® (T Cell Engaging Receptors), in which one binding region targets MAGEA4/8, a highly prevalent antigen in multiple solid tumors, and the other region engages and activates T cells. In preclinical proof-of-concept studies, IMA401 has shown anti-tumor activity with complete remissions in various in vivo tumor models including patient-derived xenograft models. The agreement outlines a development plan under which both companies will collaborate to advance the program through clinical development. In November 2021, Immatics filed a Clinical Trial Application (CTA) with Paul-Ehrlich-Institute (PEI), the German federal regulatory authority, for the development of IMA401. The clinical trial, which is planned to commence in the first half of 2022, will enroll patients across various solid tumor types.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Immatics N.V. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Immatics N.V. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022

2021-11-20 00:00:00

LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022.

Neutral

Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022

2021-11-13 00:00:00

Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022. Venue: Amsterdam, Netherlands.

Neutral

Immatics N.V. - Special Call

2021-11-09 13:08:00

To discuss these clinical data and the company’s comprehensive strategy to target PRAME via different programs

Positive

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

2021-11-09 13:00:00

Immatics N.V. announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine® IMA203 targeting PRAME. Data from patients treated at the first three of four dose levels of the ongoing IMA203 Phase 1a dose escalation study show a high preliminary objective response rate (partial responses according to RECIST 1.1) at doses below 1 billion total transduced cells. The data will be presented as a late-breaking oral presentation on Saturday, November 13 at 12:00-12:15 pm EST at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In addition, Immatics will present preclinical proof-of-concept data for its next-generation IMA203CD8 candidate at the SITC Annual Meeting on Friday, November 12 and will provide an overall update on all IMA200 programs including IMA201 (MAGEA4/A8) and IMA202 (MAGEA1) in a conference call on November 9, 2021 at 8:30 am EST. In the ongoing ACTengine® IMA203 trial, Immatics is treating advanced solid cancer patients utilizing TCR-T cells directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). PRAME is homogenously expressed and highly prevalent across several solid cancer indications. The chosen PRAME target peptide has been identified by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT®, demonstrating natural and specific occurrence of the target on tumors at high copy numbers.

Neutral

Immatics N.V. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021

2021-11-02 14:13:00

Immatics N.V. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 . Venue: London, United Kingdom.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Immatics N.V. Presents at Festival of Biologics Basel 2021, Nov-09-2021 through Nov-11-2021

2021-10-11 18:52:00

Immatics N.V. Presents at Festival of Biologics Basel 2021, Nov-09-2021 through Nov-11-2021. Venue: Congress Centre, Basel, Switzerland. Presentation Date & Speakers: Nov-09-2021, Ali Mohamed, Vice President, CMC.

Neutral

Immatics N.V. Presents at Antibody Engineering & Therapeutics US, Dec-15-2021 03:15 PM

2021-10-06 12:38:00

Immatics N.V. Presents at Antibody Engineering & Therapeutics US, Dec-15-2021 03:15 PM. Venue: Marriott Marquis San Diego, San Diego, California, United States. Speakers: Dominik Maurer, Vice President and Global Head of Immunology.

Neutral

Immatics N.V. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021

2021-09-16 14:42:00

Immatics N.V. Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021 . Speakers: Ali Mohamed, Ali Mohamed.

Neutral

Immatics N.V. Presents at Advanced Therapies Connect, Sep-28-2021 01:30 PM

2021-09-09 09:19:00

Immatics N.V. Presents at Advanced Therapies Connect, Sep-28-2021 01:30 PM. Speakers: Delfi Krishna, Head of Strategic Operations, Cell & Gene Therapy.

Neutral

Clarion Events Limited, Advanced Therapies Connect, Sep 28, 2021 through Sep 29, 2021

2021-09-09 04:36:00

Clarion Events Limited, Advanced Therapies Connect, Sep 28, 2021 through Sep 29, 2021.

Neutral

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021

2021-09-08 23:01:00

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021.

Neutral

Immatics N.V. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 through Sep-03-2021

2021-08-24 14:32:00

Immatics N.V. Presents at 6th Annual CAR-TCR Summit, Aug-30-2021 through Sep-03-2021. Venue: Hynes Convention Center, Boston, Massachusetts, United States. Presentation Date & Speakers: Aug-30-2021, Delfi Krishna, Head of Strategic Operations Cell & Gene Therapy. Aug-31-2021, Cedrik M. Britten, Chief Medical Officer, Delfi Krishna, Head of Strategic Operations.

Neutral

Immatics N.V. Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-27-2021 04:30 PM

2021-08-14 17:42:00

Immatics N.V. Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-27-2021 04:30 PM. Speakers: Delfi Krishna, Head of Strategic Operations Cell & GTx.

Neutral

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021

2021-08-14 15:18:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021.

Neutral

Immatics N.V. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 11:00 AM

2021-08-04 12:33:00

Immatics N.V. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 11:00 AM. Speakers: Arnd Christ, Chief Financial Officer, Harpreet Singh, CEO, MD, Member of Management Board & Supervisory Director, Jordan Silverstein, Head of Strategy, Sabrina Kuttruff, Business Development Manager.

Neutral

Immatics N.V. has filed a Shelf Registration in the amount of $500 million.

2021-08-02 00:00:00

Immatics N.V. has filed a Shelf Registration in the amount of $500 million. Security Name: Ordinary shares Security Name: Debt securities Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Negative

Immatics N.V. has filed a Follow-on Equity Offering in the amount of $100 million.

2021-08-02 00:00:00

Immatics N.V. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering

Positive

Biocopy AG and Immatics Enter into a Collaboration to Characterize T Cell Receptor - Peptide-HLA Interactions

2021-07-07 07:00:00

BioCopy AG announced a collaboration with Immatics N.V. Immatics in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things. Cancer represents one of the most frequent causes of death and thus one of the great challenges of modern medicine. Therefore, it is not only necessary but crucial to develop advanced therapies. For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes. With this technology BioCopy is contributing a safety screening for novel TCR-based cancer cell therapies. The extension of BioCopy's highly innovative screening platform to provide insight into T cell responses in addition to B-cell responses is a valuable milestone for BioCopy. During the last months, BioCopy has been working to develop this globally unique screening, and a patent application has already been filed on the technology. The goal of this collaboration is to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously. This ultra-high-throughput approach could significantly accelerate the development of T cell based cancer therapies by facilitating large pre-clinical safety screenings. Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. The BioCopy technology will be implemented as part of Immatics' XCEPTOR® platform, which delivers highly specific TCRs for the development of Adoptive Cell Therapies and TCR Bispecifics.

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Fundamental Summary

At a high level, the metrics from Immatics's Q1 financial report release were demonstrably positive. Their growth, value, and income factors performance indicate that company management is focused on the right targets and executing well. We expect that this positive performance will continue in the coming months, and anticipate that Immatics will maintain good momentum even in a challenging environment. We gave Immatics a 84 rating and a BUY recommendation.

Immatics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net income was EUR 85.66 million compared to net loss of EUR 22.81 million a year ago. Basic earnings per share from continuing operations was EUR 1.36 compared to basic loss per share from continuing operations of EUR 0.36 a year ago. Diluted earnings per share from continuing operations was EUR 1.35 compared to diluted loss per share from continuing operations of EUR 0.36 a year ago.

Business Description

Immatics, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company’s TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics is headquartered in Tübingen, Germany.

Sector Overview

Immatics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Immatics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 282.2 61.6% 70
Liabilities 166.2 10.4% 56
Price to Book 4.3 -86.2% 73
Cash & Equivalents 247.3 86.0% 95
Equity 116.0 382.0% 84
EBITDA 11.7 114.5% 93
Total Revenues 130.3 274.7% 37
Parameter Value Change Score
Return on Equity 15.8 109.4% 53
Net Cashflow 52.0 169.7% 82
Capital Expenditure -5.7 -11.6% 56
Asset Turnover 0.5 209.4% 99
Free Cashflow 0.6 143.1% 95

* All values are TTM

The below chart reflects Immatics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Immatics's peer average final assessment score stands on 65.0, Immatics's score is 84.

  •  IMTX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 1 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 2 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 3 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 4 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 6 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 7 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 8 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 9 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 10 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 11 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 12 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 13 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Immatics's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Immatics's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 73.

Bullish 73
Close Price 8.56
52W Low 6.0
52W High 15.46
5D MA 8.41
50D MA 7.66
200D MA 10.16
MACD 0.26
RSI 13.13
STOCH 72.38

Balance Sheet Analysis

Overall, Immatics's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Immatics reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 247.3, representing 86.0% change from the last report. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. Therefore, its cash and cash equivalents movement earned a score of 95. Also, Immatics reported solid equity numbers this period. At filing, equity was reported as 116.0, representing 382.0% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 7.3 percent by this parameter. These metrics are all the more impressive relative to their peers and should support an upswing in their stock price. The company's equity movement component, therefore, received a grade of 84. That said, one metric, Liabilities, stood out as particularly concerning. At filing, Immatics's liabilities were 166.2, representing a 10.4% change from the previous period. Immatics's liabilities changes appear mediocre compared to their peers. Contextually, they convey that management finds balancing asset growth, resource allocation, and liabilities challenging. Discouraging results like these statistically lead to negative movement in stock prices, so we rated their liabilities movement component 56. Consequently, its balance sheet earned a rank of 76.

Parameter Value Change Score
Assets 282.2 61.6% 70
Liabilities 166.2 10.4% 56
Price to Book 4.3 -86.2% 73
Cash & Equivalents 247.3 86.0% 95
Equity 116.0 382.0% 84
* All values are TTM

The below chart describes Immatics's performance as reflected on its balance sheet with respect to its peers. While Immatics received a balance sheet score of 76, the average of its peers stands on 66.0.

  •  IMTX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 1 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 2 1
Vericel Corporation 1.1B 51 65 56 53 61 57 3 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 4 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 6 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 7 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 8 1
Agenus Inc. 520.5M 73 62 37 55 60 54 9 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 10 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 11 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 12 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 13 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Immatics appears likely to maintain its strong income statement metrics and momentum going forward. Immatics reported impressive EBITDA this period. At filing, EBITDA was reported as 11.7, representing 114.5% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Consequently, their EBITDA movement received a grade of 93. Also, Immatics's reported return on equity (ROE) ratio was 15.8, representing a change of 109.4%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their return factors received a grade of 53. That said, one metric, Revenue Efficiency, stood out as particularly concerning. Immatics reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 130.3 and represented 274.7% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. Consequently, their revenue efficiency received a grade of 37. Therefore, it received a score of 77.

Parameter Value Change Score
EBITDA 11.7 114.5% 93
Total Revenues 130.3 274.7% 37
Return on Equity 15.8 109.4% 53
* All values are TTM

The below chart describes Immatics's performance as reflected on its income statement with respect to its peers. While Immatics received a income statement score of 77 , the average of its peers stands on 61.0.

  •  IMTX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 1 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 2 1
Vericel Corporation 1.1B 76 44 82 56 3 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 4 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 6 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 7 1
CTI BioPharma Corp. 603.6M 84 50 62 59 8 1
Agenus Inc. 520.5M 57 83 45 74 9 1
Vaxart, Inc. 440.0M 99 51 72 68 10 1
MiMedx Group, Inc. 391.5M 87 43 83 59 11 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 12 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 13 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two metrics jump up as the most significant positive drivers of the cash flow's strength in Immatics's recent report: Asset Turnover and Free Cash flow. Immatics is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.5, representing a 209.4% change from the previous period. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Correspondingly, their asset turnover movement received a grade of 99. Also, Immatics's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Immatics recorded free cash flow of 0.6, which represents a 143.1% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Therefore, its free cash flow movement earned a score of 95. That said, one metric, Capital Expenditure, stood out as strongly negative. Immatics's management was ineffective in materially improving CapEx, which now sits at -5.7 and represents a -11.6% change from the previous report. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Its CapEx movement, therefore, received a grade of 56. Its cash flow, therefore, earned a score of 86.

Parameter Value Change Score
Net Cashflow 52.0 169.7% 82
Capital Expenditure -5.7 -11.6% 56
Asset Turnover 0.5 209.4% 99
Free Cashflow 0.6 143.1% 95
* All values are TTM

The below chart describes Immatics's performance as reflected on its cash flow with respect to its peers. While Immatics received a cash flow score of 86, the average of its peers stands on 70.0.

  •  IMTX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 1 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 2 1
Vericel Corporation 1.1B 64 46 59 73 65 3 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 4 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 6 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 7 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 8 1
Agenus Inc. 520.5M 57 43 52 77 58 9 1
Vaxart, Inc. 440.0M 72 56 53 38 65 10 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 11 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 12 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 13 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.